APOL1 gene is a member of APOL gene family, which plays an important role in innate immunity, which is our body’s built-in defense system to fight threats. Some variations in APOL1 gene cause damage to parts within the kidney. Damage to parts that filter blood can lead to severe kidney disease or ultimately kidney failure. An example of such an indication is focal segmental glomerulosclerosis (FSGS), which is a type of kidney disease that can be caused by APOL1 gene variations.
This report contains market size and forecasts of APOL1 Mediated Kidney Disease in Global, including the following market information:
Global APOL1 Mediated Kidney Disease Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global APOL1 Mediated Kidney Disease market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Small Molecule Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of APOL1 Mediated Kidney Disease include Vertex Pharmaceuticals, Ionis Pharmaceuticals, Travere Therapeutics, ChemoCentryx, ZyVersa Therapeutics, GlaxoSmithKline, Novartis and Teva Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the APOL1 Mediated Kidney Disease companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global APOL1 Mediated Kidney Disease Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global APOL1 Mediated Kidney Disease Market Segment Percentages, by Type, 2021 (%)
Small Molecule
Gene Modification
Nucleic Acid Therapies
Others
Global APOL1 Mediated Kidney Disease Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global APOL1 Mediated Kidney Disease Market Segment Percentages, by Application, 2021 (%)
Chronic Kidney Disease
End Stage Kidney Disease
Global APOL1 Mediated Kidney Disease Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global APOL1 Mediated Kidney Disease Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies APOL1 Mediated Kidney Disease revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies APOL1 Mediated Kidney Disease revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Vertex Pharmaceuticals
Ionis Pharmaceuticals
Travere Therapeutics
ChemoCentryx
ZyVersa Therapeutics
GlaxoSmithKline
Novartis
Teva Pharmaceuticals